Advertisement

European Journal of Clinical Pharmacology

, Volume 74, Issue 11, pp 1397–1403 | Cite as

Clinical pharmacodynamics and long-term efficacy of Talcom vs. Plavix in patients undergoing coronary stent implantation: a randomized study with 5-year follow-up

  • Jinshuang Li
  • Yuansheng Fan
  • Tiantian Zhu
  • Jun Chen
  • Deyu Kong
  • Haoyu Meng
  • Jing Zhang
  • Ke Xu
  • Sen Ye
  • Yuqin Ji
  • Chunjian Li
Pharmacodynamics
  • 75 Downloads

Abstract

Purpose

Form II clopidogrel bisulfate (Plavix) has been extensively used in patients with acute coronary syndrome. However, the efficacy of form I clopidogrel bisulfate (Talcom) was less investigated. The aim of this study was to investigate the efficacy and safety of Talcom compared with Plavix.

Method

Two hundred and forty-eight patients were recruited after receiving percutaneous coronary intervention (PCI). Participants were randomly assigned to Talcom or Plavix group, and administered with Talcom or Plavix 75 mg od respectively in combination with aspirin 100 mg od for 12 months. Primary endpoints were set as levels of adenosine diphosphate-induced platelet aggregation (PLADP) on the 5th day and at 1 month after randomization. Patients were followed-up for 5 years. Bleeding events and major adverse cardiovascular events (MACE) including cardiac death, non-fatal myocardial infarction, ischemic stroke, target lesion revascularization (TLR), and cardiogenic re-admission were recorded.

Results

On the 5th day and at 1 month after randomization, the antiplatelet effect of Talcom was non-inferior to that of Plavix [PLADP (5th day): 30% (22%, 43%) vs. 33% (22%, 44%), p = 0.007; PLADP (1 month): 29% (19%, 43%) vs. 31% (22%, 43%), p = 0.005]. A total of 208 patients completed the follow-up, the incidences of MACE and bleeding were both comparable, and the MACE-free survival did not differ between the two groups. However, the expenditure was 32% lower for Talcom compared to Plavix during the treatment period.

Conclusions

The antiplatelet effect of Talcom is non-inferior to Plavix, and the clinical efficacy and safety of Talcom and Plavix at 5 years were not significantly different in this study.

Keywords

Clopidogrel Plavix Talcom Platelet aggregation Non-inferiority trial 

Notes

Statement on contributorship and the guarantor

JSL, YSF, TTZ, and JC collected the primary data and undertook the initial data analysis; all authors contributed to the drafting of this manuscript. CJL acts as guarantor.

Fundings

This study was supported by a grant from the National Natural Foundation of China (Grant No.81170181), a grant from the Jiangsu Province’s Key Provincial Talents Program (ZDRCA2016013), and a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutes (PAPD).

Compliance with ethical standards

This research was approved by the Research Ethics Board of the First Affiliated Hospital of Nanjing Medical University.

Conflict of interest

The authors have no conflict of interest to declare.

References

  1. 1.
    Koradia V, Chawla G, Bansal AK (2004) Qualitative and quantitative analysis of clopidogrel bisulphate polymorphs. Acta Pharma 54(3):193–204Google Scholar
  2. 2.
    Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Juni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN, Group ESCSD, Guidelines ESCCfP, Societies ESCNC (2017) 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 39:213–260.  https://doi.org/10.1093/eurheartj/ehx419 CrossRefGoogle Scholar
  3. 3.
    Khalili H, Singh R, Wood M, Edwards A, Cooper M, Ayers C, Moss E, Berry JD, Vongpatanasin W, de Lemos JA, Das SR (2016) Premature clopidogrel discontinuation after drug-eluting stent placement in a large urban safety-net hospital. Am J Cardiol 117(4):522–525.  https://doi.org/10.1016/j.amjcard.2015.11.037 CrossRefPubMedGoogle Scholar
  4. 4.
    Grines CL, Bonow RO, Casey DE, Gardner TJ, Lockhart PB, Moliterno DJ, O’Gara P, Whitlow P (2007) Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. J Am Dent Assoc 138(5):652–655.  https://doi.org/10.14219/jada.archive.2007.0237 CrossRefPubMedGoogle Scholar
  5. 5.
    Meng KLS, Zhu HG et al (2010) Use of tailored loading dose clopidogrel in patients undergoing selected percutaneous coronary intervention based on adenosine diphosphate-mediated platelet aggregation. Chin Med J 123(24):3578–3582PubMedGoogle Scholar
  6. 6.
    Li C, Hirsh J, Sloane D, Liang Y, Bai J, Paikin J, Johnston MA, DeBeer J, Eikelboom JW (2012) Aspirin response variability after major orthopedic surgery. Thromb Res 130(2):216–220.  https://doi.org/10.1016/j.thromres.2012.04.006 CrossRefPubMedGoogle Scholar
  7. 7.
    Li C, Hirsh J, Xie C, Johnston MA, Eikelboom JW (2012) Reversal of the anti-platelet effects of aspirin and clopidogrel. J Thromb Haemost Jth 10(4):521–528CrossRefGoogle Scholar
  8. 8.
    Gurbel PA, Bliden KP, Saucedo JF, Suarez TA, Di Chiara J, Antonino MJ, Mahla E, Singla A, Herzog WR, Bassi AK, Hennebry TA, Gesheff TB, Tantry US (2009) Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study. J Am Coll Cardiol 53(8):648–657.  https://doi.org/10.1016/j.jacc.2008.10.045 CrossRefPubMedGoogle Scholar
  9. 9.
    Steinhubl SR, Kastrati A, Berger PB (2007) Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs. Am Heart J 154(1):3–11.  https://doi.org/10.1016/j.ahj.2007.04.009 CrossRefPubMedGoogle Scholar
  10. 10.
    Zaid AN, Al Ramahi R, Bustami R, Mousa A, Khasawneh S (2015) Comparative fasting bioavailability of two clopidogrel formulations in healthy Mediterranean volunteers: an in vitro-in vivo correlation. Drug Des Devel Ther 9:2359–2365.  https://doi.org/10.2147/DDDT.S78658 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Ohkubo K, Fujimoto Y, Iwata Y, Kitahara H, Kadohira T, Sugimoto K, Morino T, Kobayashi Y (2014) Efficacy and safety of low-dose clopidogrel in Japanese patients after drug-eluting stent implantation: a randomized pilot trial. Heart Vessel 29(1):1–6.  https://doi.org/10.1007/s00380-012-0318-6 CrossRefGoogle Scholar
  12. 12.
    Muntner P, Mann DM, Woodward M, Choi JW, Stoler RC, Shimbo D, Farkouh ME, Kim MC (2011) Predictors of low clopidogrel adherence following percutaneous coronary intervention. Am J Cardiol 108(6):822–827.  https://doi.org/10.1016/j.amjcard.2011.04.034 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Quadros AS, Welter DI, Camozzatto FO, Chaves A, Mehta RH, Gottschall CA, Lopes RD (2011) Identifying patients at risk for premature discontinuation of thienopyridine after coronary stent implantation. Am J Cardiol 107(5):685–689.  https://doi.org/10.1016/j.amjcard.2010.10.045 CrossRefPubMedGoogle Scholar
  14. 14.
    Biondi-Zoccai GG, Agostoni P, Sangiorgi GM, Airoldi F, Cosgrave J, Chieffo A, Barbagallo R, Tamburino C, Vittori G, Falchetti E, Margheri M, Briguori C, Remigi E, Iakovou I, Colombo A, Real-world Eluting-stent Comparative Italian retrosPective Evaluation Study I (2006) Incidence, predictors, and outcomes of coronary dissections left untreated after drug-eluting stent implantation. Eur Heart J 27(5):540–546.  https://doi.org/10.1093/eurheartj/ehi618 CrossRefPubMedGoogle Scholar
  15. 15.
    Moreno R, Fernandez C, Hernandez R, Alfonso F, Angiolillo DJ, Sabate M, Escaned J, Banuelos C, Fernandez-Ortiz A, Macaya C (2005) Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 45(6):954–959.  https://doi.org/10.1016/j.jacc.2004.11.065 CrossRefPubMedGoogle Scholar
  16. 16.
    Tapp L, Shantsila E, Lip GY (2010) Role of ticagrelor in clopidogrel nonresponders: resistance is futile? Circulation 121(10):1169–1171CrossRefGoogle Scholar
  17. 17.
    Sackett DL, Richardson W, Rosenberg W et al (1997) Evidence-based medicine: how to practice and teach EBM. Churchill Livingstone, New YorkGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Jinshuang Li
    • 1
    • 2
  • Yuansheng Fan
    • 1
  • Tiantian Zhu
    • 3
  • Jun Chen
    • 4
  • Deyu Kong
    • 5
  • Haoyu Meng
    • 1
  • Jing Zhang
    • 1
  • Ke Xu
    • 1
  • Sen Ye
    • 1
  • Yuqin Ji
    • 1
  • Chunjian Li
    • 1
  1. 1.Department of CardiologyThe First Affiliated Hospital of Nanjing Medical UniversityNanjingChina
  2. 2.Department of CardiologySuqian Hospital Affiliated of Xuzhou Medical UniversitySuqianChina
  3. 3.Department of CardiologyThe Affiliated Jiangning Hospital of Nanjing Medical UniversityNanjingChina
  4. 4.Department of CardiologyPeople’s Hospital of MaanshanMaanshanChina
  5. 5.Department of CardiologyJining First People’s HospitalJiningChina

Personalised recommendations